Dr. Raksha Rao, R17558, Dr. Vishalsharma, Dr. Santosh G Honavar
Purpose: To evaluate the safety and efficacy of intravitreal topotecan (IViT) for refractory vitreous seeds in retinoblastoma.
Methods: IViT injection (30 μg in 0.15 mL) was provided by the safety-enhanced technique
Results: Thirty six eyes of 35 patients received a mean of 3 (range 2-7) 3-weekly IViT injections. Prior treatment included chemotherapy with focal consolidation in all, periocular carboplatin in 28, and intravitreal melphalan in 7. Complete regression of vitreous seeds was achieved in 36 of 36 eyes (100%) at a mean follow-up of 11 months. One eye (3%) with a recurrent retinal tumor needed enucleation. No ocular or systemic complication was observed at the last follow-up. Visual acuity remained stable or improved in all.
Conclusion: Spaced-out IViT monotherapy for refractory vitreous seeds in retinoblastoma appears safe and potent.